| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Edward A Lock, Jing Zhang, Harvey Checkowa. Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence. Toxicology and applied pharmacology. vol 266. issue 3. 2013-05-29. PMID:23220449. |
parkinson disease (pd) is a debilitating neurodegenerative motor disorder, with its motor symptoms largely attributable to loss of dopaminergic neurons in the substantia nigra. |
2013-05-29 |
2023-08-12 |
human |
| Mei Yu, Haiyun Suo, Ming Liu, Lei Cai, Jie Liu, Yufang Huang, Jing Xu, Yancong Wang, Cuiqing Zhu, Jian Fei, Fang Huan. NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP. Neurobiology of aging. vol 34. issue 3. 2013-05-24. PMID:22766071. |
also, the reduction of tyrosine hydroxylase protein in the striatum and the loss of dopaminergic neurons in the substantia nigra were more severe in the cko mice. |
2013-05-24 |
2023-08-12 |
mouse |
| Kathleen J Griffioen, Sarah M Rothman, Bruce Ladenheim, Ruiqian Wan, Neil Vranis, Emmette Hutchison, Eitan Okun, Jean Lud Cadet, Mark P Mattso. Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant α-synuclein. Neurobiology of aging. vol 34. issue 3. 2013-05-24. PMID:22883907. |
results of autopsy studies suggest that brainstem pathology, including the accumulation of α-synuclein, precedes damage to dopaminergic neurons in the substantia nigra in pd. |
2013-05-24 |
2023-08-12 |
mouse |
| P De Deurwaerdère, S Navaille. What can we expect from the serotonergic side of L-DOPA? Revue neurologique. vol 168. issue 12. 2013-05-21. PMID:22560009. |
parkinson's disease has long been associated with neurodegeneration of the dopaminergic neurons located in the substantia nigra. |
2013-05-21 |
2023-08-12 |
Not clear |
| Yoichi Imaizumi, Yohei Okada, Wado Akamatsu, Masato Koike, Naoko Kuzumaki, Hideki Hayakawa, Tomoko Nihira, Tetsuro Kobayashi, Manabu Ohyama, Shigeto Sato, Masashi Takanashi, Manabu Funayama, Akiyoshi Hirayama, Tomoyoshi Soga, Takako Hishiki, Makoto Suematsu, Takuya Yagi, Daisuke Ito, Arifumi Kosakai, Kozo Hayashi, Masanobu Shouji, Atsushi Nakanishi, Norihiro Suzuki, Yoshikuni Mizuno, Noboru Mizushima, Masayuki Amagai, Yasuo Uchiyama, Hideki Mochizuki, Nobutaka Hattori, Hideyuki Okan. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Molecular brain. vol 5. 2013-05-15. PMID:23039195. |
parkinson's disease (pd) is a neurodegenerative disease characterized by selective degeneration of dopaminergic neurons in the substantia nigra (sn). |
2013-05-15 |
2023-08-12 |
mouse |
| Chengyu Sheng, Xin Heng, Guannan Zhang, Ran Xiong, Hui Li, Shi Zhang, Shengdi Che. DJ-1 deficiency perturbs microtubule dynamics and impairs striatal neurite outgrowth. Neurobiology of aging. vol 34. issue 2. 2013-04-29. PMID:22609282. |
parkinson's disease (pd) is a common neurodegenerative disease characterized by the selective loss of the dopaminergic (da) neurons in substantia nigra. |
2013-04-29 |
2023-08-12 |
mouse |
| Gao Rui, Zhang Guangjian, Wang Yong, Feng Jie, Cui Yanchao, Jia Xi, Li Fe. High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats. Behavioural brain research. vol 237. 2013-04-26. PMID:23036843. |
ea at 100 hz was shown to significantly enhance survival of dopaminergic neurons in the substantia nigra (52.10 ± 11.41% of the level on the non-lesioned rats vs. 21.22 ± 5.52% in the non-ea group, p<0.05) and reduce motor deficits (207.80 ± 31.14 vs. 476.11 ± 68.80 turns/30 min, p<0.05), whereas it only slightly restored the 6-hydroxydopamine-induced loss of striatal da (p>0.05 vs. the non-ea group). |
2013-04-26 |
2023-08-12 |
rat |
| Maurizio F Facheris, Andrew A Hicks, Peter P Pramstaller, Irene Pichle. Update on the management of restless legs syndrome: existing and emerging treatment options. Nature and science of sleep. vol 2. 2013-04-26. PMID:23616710. |
rls patients have lower dopamine and iron levels in the substantia nigra and respond to both dopaminergic therapy and iron administration. |
2013-04-26 |
2023-08-12 |
Not clear |
| Jun Kim, Ji-Won Byun, Insup Choi, Beomsue Kim, Hey-Kyeong Jeong, Ilo Jou, Eunhye Jo. PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices. Experimental neurobiology. vol 22. issue 1. 2013-04-16. PMID:23585721. |
parkinson's disease (pd) is the second most common neurodegenerative motor disease caused by degeneration of dopaminergic neurons in the substantia nigra. |
2013-04-16 |
2023-08-12 |
Not clear |
| Lanying Song, Yuxi Shan, K C Kent Lloyd, Gino A Cortopass. Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression. Human molecular genetics. vol 21. issue 23. 2013-04-12. PMID:22949510. |
parkinson's disease (pd) is the second most common neurodegenerative disorder in the developed world, and is characterized by the loss of dopaminergic (da) neurons in the substantia nigra (sn). |
2013-04-12 |
2023-08-12 |
mouse |
| Terina N Martinez, Xi Chen, Sibali Bandyopadhyay, Alfred H Merrill, Malú G Tanse. Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Molecular neurodegeneration. vol 7. 2013-04-09. PMID:22973882. |
dopaminergic (da) neurons in the ventral midbrain selectively degenerate in parkinson's disease (pd) in part because their oxidative environment in the substantia nigra (sn) may render them vulnerable to neuroinflammatory stimuli. |
2013-04-09 |
2023-08-12 |
rat |
| Begoña Villar-Cheda, Antonio Dominguez-Meijide, Belen Joglar, Ana I Rodriguez-Perez, Maria J Guerra, Jose L Labandeira-Garci. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiology of disease. vol 47. issue 2. 2013-04-03. PMID:22542954. |
in the substantia nigra of mice, administration of the dopaminergic neurotoxin mptp induced an increase in the expression of rhoa and rock ii mrna levels and rock activity, which were inhibited by at1 receptor deletion (i.e., in at1a null mice treated with mptp). |
2013-04-03 |
2023-08-12 |
mouse |
| Hyun-Jung Park, Jin Young Shin, Bo Ra Lee, Hyun Ok Kim, Phil Hyu Le. Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model. Cell transplantation. vol 21. issue 8. 2013-04-01. PMID:22546197. |
mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model. |
2013-04-01 |
2023-08-12 |
human |
| F L Campos, A C Cristovão, S M Rocha, C P Fonseca, G Baltaza. GDNF contributes to oestrogen-mediated protection of midbrain dopaminergic neurones. Journal of neuroendocrinology. vol 24. issue 11. 2013-03-28. PMID:22672424. |
parkinson's disease (pd) is characterised by the preferential loss of dopaminergic neurones from the substantia nigra (sn) that leads to the hallmark motor disturbances. |
2013-03-28 |
2023-08-12 |
human |
| Gulay Hacioglu, Yasemin Seval-Celik, Gamze Tanriover, Ozlem Ozsoy, Esen Saka-Topcuoglu, Sevin Balkan, Aysel Aga. Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease. Folia histochemica et cytobiologica. vol 50. issue 2. 2013-03-26. PMID:22763967. |
the dopaminergic lesion was determined by immunohistochemical analysis for tyrosine hydroxylase (th)-immunopositive cells in substantia nigra (sn). |
2013-03-26 |
2023-08-12 |
rat |
| Tian-Fang Jiang, Sheng-Di Che. Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets? Neuroscience bulletin. vol 28. issue 5. 2013-03-26. PMID:22961477. |
parkinson's disease (pd) is pathologically characterized by the presence of α-synuclein (α-syn)-positive intracytoplasmic inclusions named lewy bodies in the dopaminergic neurons of the substantia nigra. |
2013-03-26 |
2023-08-12 |
Not clear |
| Ming Lu, Gang H. Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies. Clinical and experimental pharmacology & physiology. vol 39. issue 6. 2013-03-25. PMID:22126374. |
in particular, inflammation plays a critical role in the destruction of both pancreatic islet β-cells and dopaminergic neurons in the substantia nigra. |
2013-03-25 |
2023-08-12 |
Not clear |
| Dana M Annerino, Shawn Arshad, Georgia M Taylor, Charles H Adler, Thomas G Beach, James G Green. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta neuropathologica. vol 124. issue 5. 2013-03-25. PMID:22941241. |
although pd has traditionally been considered a disease of dopaminergic neurons in the substantia nigra, analyses of gastrointestinal samples from pd patients have consistently revealed pathology in the enteric nervous system. |
2013-03-25 |
2023-08-12 |
Not clear |
| J A Moreno-Bravo, J E Martinez-Lopez, E Puelle. Mesencephalic neuronal populations: new insights on the ventral differentiation programs. Histology and histopathology. vol 27. issue 12. 2013-03-21. PMID:23059883. |
this segment of the brain contains, in the dorsal part, structures such as the collicula (superior and inferior), tectal grey and the preisthmic segment, and in the basal plate, neuronal populations such as the oculomotor complex, the dopaminergic substantia nigra and the ventral tegmental area, the reticular formation and the periacueductal grey. |
2013-03-21 |
2023-08-12 |
Not clear |
| Rajeswara B Mythri, Gangadharappa Harish, M M Bharat. Therapeutic potential of natural products in Parkinson's disease. Recent patents on endocrine, metabolic & immune drug discovery. vol 6. issue 3. 2013-03-14. PMID:22827714. |
the central objective in treating patients with parkinson's disease (pd) is two-fold (i) to increase the striatal dopamine content and (ii) to prevent further degeneration of the surviving dopaminergic neurons in the substantia nigra region of the ventral midbrain. |
2013-03-14 |
2023-08-12 |
Not clear |